Mark L. Baum
2015
In 2015, Mark L. Baum earned a total compensation of $3.2M as Chief Executive Officer at Imprimis Pharmaceuticals, a 412% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $114,369 |
|---|---|
| Option Awards | $2,783,577 |
| Salary | $338,870 |
| Other | $10,600 |
| Total | $3,247,416 |
Baum received $2.8M in option awards, accounting for 86% of the total pay in 2015.
Baum also received $114.4K in non-equity incentive plan, $338.9K in salary and $10.6K in other compensation.
Rankings
In 2015, Mark L. Baum's compensation ranked 2,867th out of 13,638 executives tracked by ExecPay. In other words, Baum earned more than 79.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,867 out of 13,638 | 79th |
Division Manufacturing | 1,014 out of 5,190 | 81st |
Major group Chemicals And Allied Products | 374 out of 1,854 | 80th |
Industry group Drugs | 291 out of 1,528 | 81st |
Industry Pharmaceutical Preparations | 231 out of 1,182 | 81st |
Source: SEC filing on April 27, 2017.
Baum's colleagues
We found two more compensation records of executives who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2015.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019